Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
Most Cited Paper
in Immunotherapy and Immune Responses
18 Months Post-Publication
Class of 2026
“Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026/
Topics
Claudin18.2 · CAR T-cell therapy · gastrointestinal cancers · Phase I clinical trial · Claudin18.2-specific CAR T cells · tumor-associated antigen · solid tumor immunotherapy · CAR T cell therapy toxicity · Objective response rate (ORR) · gastric cancer · pancreatic cancer · esophageal cancer · CLDN18.2 expression · cytokine release syndrome · on-target off-tumor toxicity · CAR T cell persistence · antitumor efficacy
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026. https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026. Accessed 2026-07-20. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459